Result of AGM

SkinBioTherapeutics PLC

29 December 2023

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or the "Company")

Results of AGM

29 December 2023 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

Resolution		For & Discretionary		Against		Withheld
		Number of votes	%	Number of votes	%	Number of votes	%
01	Ordinary resolution to receive and adopt the directors' and auditors' report and the financial statements for year ended 30 June 2023	43,029,848	96.78%	1,413,649	3.18%	17,051	0.04%
02	Ordinary resolution for Gravita Audit Limited to be re-appointed as the auditors of the Company until the next AGM	42,677,600	95.99%	448,075	1.01%	1,334,873	3.00%
03	Ordinary resolution for the Directors' to be authorised to fix the auditors' remuneration	42,958,431	96.62%	186,707	0.42%	1,315,410	2.96%
04	Ordinary resolution for Stuart Ashman to be re-elected as a Director of the Company	39,303,678	88.40%	2,636,183	5.93%	2,520,687	5.67%
05	Ordinary resolution for Martin Hunt to be re-elected as a Director of the Company	39,991,885	89.95%	2,248,346	5.06%	2,220,317	4.99%
06	Ordinary resolution for Dr Catherine Prescott to be re-elected as a Director of the Company	40,063,946	90.11%	3,072,834	6.91%	1,323,768	2.98%
07	Ordinary resolution for Danielle Bekker to be re-elected as a Director of the Company	42,059,615	94.60%	972,653	2.19%	1,428,280	3.21%
08	Ordinary resolution for Manprit Singh Randhawa to be re-elected as a Director of the Company	39,716,379	89.33%	2,419,340	5.44%	2,324,829	5.23%
09	Ordinary resolution to authorise the directors to allot shares	42,030,813	94.54%	1,096,351	2.47%	1,333,384	3.00%
10	Special resolution to authorise the directors to disapply pre-emption rights	42,285,656	95.11%	822,045	1.85%	1,352,847	3.04%
11	Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment	42,302,981	95.15%	804,720	1.81%	1,352,847	3.04%

-Ends-

For more information, please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Jack Kincade	Tel: [phone] SkinBioTherapeutics @instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

END